Sanja Trifkovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sanja Trifkovic has a total of 266 co-authors. Here are the top co-authors by number of shared publications:
- Richard J. Webby
Department of Host-Microbe Interactions, St. Jude Children’s Research Hospital
10 shared publications Trushar Jeevan
Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, USA
6 shared publications- Ahmed Kandeil
Department of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN, USA
4 shared publications Jennifer DeBeauchamp
Department of Host–Microbe Interactions, St. Jude Children’s Research Hospital, Memphis, USA
4 shared publicationsJohn Franks
Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, USA
4 shared publicationsLance Miller
Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, USA
4 shared publications
Latest Publications
- Open Access
- 28 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer
The zoonotic origin of the COVID-19 pandemic virus highlights the need to fill the vast gaps in our knowledge of SARS-CoV-2 ecology and evolution in non-human hosts. Here, we detected that SARS-CoV-2 was introduced from humans into white-tailed deer more than 30 times in Ohio, USA during November 2021-March 2022. Subsequently, deer-to-deer transmission persisted for 2–8 months, disseminating across hundreds of kilometers. Newly developed Bayesian phylogenetic methods quantified how SARS-CoV-2 evolution is not only three-times faster in white-tailed deer compared to the rate observed in humans but also driven by different mutational biases and selection pressures. The long-term effect of this accelerated evolutionary rate remains to be seen as no critical phenotypic changes were observed in our animal models using white-tailed deer origin viruses. Still, SARS-CoV-2 has transmitted in white-tailed deer populations for a relatively short duration, and the risk of future changes may have serious consequences for humans and livestock.
- 28 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Open AccessAccelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer
The zoonotic origin of the COVID-19 pandemic virus highlights the need to fill the vast gaps in our knowledge of SARS-CoV-2 ecology and evolution in non-human hosts. Here, we detected that SARS-CoV-2 was introduced from humans into white-tailed deer more than 30 times in Ohio, USA during November 2021-March 2022. Subsequently, deer-to-deer transmission persisted for 2–8 months, disseminating across hundreds of kilometers. Newly developed Bayesian phylogenetic methods quantified how SARS-CoV-2 evolution is not only three-times faster in white-tailed deer compared to the rate observed in humans but also driven by different mutational biases and selection pressures. The long-term effect of this accelerated evolutionary rate remains to be seen as no critical phenotypic changes were observed in our animal models using white-tailed deer origin viruses. Still, SARS-CoV-2 has transmitted in white-tailed deer populations for a relatively short duration, and the risk of future changes may have serious consequences for humans and livestock.
- 17 August 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (9) , 1511-1526
Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology
Evidence suggests that innate and adaptive cellular responses mediate resistance to the influenza virus and confer protection after vaccination. However, few studies have resolved the contribution of cellular responses within the context of preexisting antibody titers. Here, we measured the peripheral immune profiles of 206 vaccinated or unvaccinated adults to determine how baseline variations in the cellular and humoral immune compartments contribute independently or synergistically to the risk of developing symptomatic influenza. Protection correlated with diverse and polyfunctional CD4+ and CD8+ T, circulating T follicular helper, T helper type 17, myeloid dendritic and CD16+ natural killer (NK) cell subsets. Conversely, increased susceptibility was predominantly attributed to nonspecific inflammatory populations, including γδ T cells and activated CD16− NK cells, as well as TNFα+ single-cytokine-producing CD8+ T cells. Multivariate and predictive modeling indicated that cellular subsets (1) work synergistically with humoral immunity to confer protection, (2) improve model performance over demographic and serologic factors alone and (3) comprise the most important predictive covariates. Together, these results demonstrate that preinfection peripheral cell composition improves the prediction of symptomatic influenza susceptibility over vaccination, demographics or serology alone.
- 17 August 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (9) , 1511-1526
Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology
Evidence suggests that innate and adaptive cellular responses mediate resistance to the influenza virus and confer protection after vaccination. However, few studies have resolved the contribution of cellular responses within the context of preexisting antibody titers. Here, we measured the peripheral immune profiles of 206 vaccinated or unvaccinated adults to determine how baseline variations in the cellular and humoral immune compartments contribute independently or synergistically to the risk of developing symptomatic influenza. Protection correlated with diverse and polyfunctional CD4+ and CD8+ T, circulating T follicular helper, T helper type 17, myeloid dendritic and CD16+ natural killer (NK) cell subsets. Conversely, increased susceptibility was predominantly attributed to nonspecific inflammatory populations, including γδ T cells and activated CD16− NK cells, as well as TNFα+ single-cytokine-producing CD8+ T cells. Multivariate and predictive modeling indicated that cellular subsets (1) work synergistically with humoral immunity to confer protection, (2) improve model performance over demographic and serologic factors alone and (3) comprise the most important predictive covariates. Together, these results demonstrate that preinfection peripheral cell composition improves the prediction of symptomatic influenza susceptibility over vaccination, demographics or serology alone.
- Open Access
- 29 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.
- 29 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-16
Open AccessCorrelates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.
- Top Cited PapersOpen Access
- 29 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America
Highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b underwent an explosive geographic expansion in 2021 among wild birds and domestic poultry across Asia, Europe, and Africa. By the end of 2021, 2.3.4.4b viruses were detected in North America, signifying further intercontinental spread. Here we show that the western movement of clade 2.3.4.4b was quickly followed by reassortment with viruses circulating in wild birds in North America, resulting in the acquisition of different combinations of ribonucleoprotein genes. These reassortant A(H5N1) viruses are genotypically and phenotypically diverse, with many causing severe disease with dramatic neurologic involvement in mammals. The proclivity of the current A(H5N1) 2.3.4.4b virus lineage to reassort and target the central nervous system warrants concerted planning to combat the spread and evolution of the virus within the continent and to mitigate the impact of a potential influenza pandemic that could originate from similar A(H5N1) reassortants.
- 29 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Top Cited PapersOpen AccessRapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America
Highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b underwent an explosive geographic expansion in 2021 among wild birds and domestic poultry across Asia, Europe, and Africa. By the end of 2021, 2.3.4.4b viruses were detected in North America, signifying further intercontinental spread. Here we show that the western movement of clade 2.3.4.4b was quickly followed by reassortment with viruses circulating in wild birds in North America, resulting in the acquisition of different combinations of ribonucleoprotein genes. These reassortant A(H5N1) viruses are genotypically and phenotypically diverse, with many causing severe disease with dramatic neurologic involvement in mammals. The proclivity of the current A(H5N1) 2.3.4.4b virus lineage to reassort and target the central nervous system warrants concerted planning to combat the spread and evolution of the virus within the continent and to mitigate the impact of a potential influenza pandemic that could originate from similar A(H5N1) reassortants.
- Open Access
- 16 February 2023
- Published by Springer Nature in Research Square
Accelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer
While SARS-CoV-2 has sporadically infected a wide range of animal species worldwide1, the virus has been repeatedly and frequently detected in white-tailed deer in North America2–7. The zoonotic origins of this pandemic virus highlight the need to fill the vast gaps in our knowledge of SARS-CoV-2 ecology and evolution in non-human hosts. Here, we detected SARS-CoV-2 was introduced from humans into white-tailed deer more than 30 times in Ohio, USA during November 2021-March 2022. Subsequently, deer-to-deer transmission persisted for 2-8 months, which disseminated across hundreds of kilometers. We discovered that alpha and delta variants evolved in white-tailed deer at three-times the rate observed in humans. Newly developed Bayesian phylogenetic methods quantified how SARS-CoV-2 evolution is not only faster in white-tailed deer but driven by different mutational biases and selection pressures. White-tailed deer are not just short-term recipients of human viral diversity but serve as reservoirs for alpha and other variants to evolve in new directions after going extinct in humans. The long-term effect of this accelerated evolutionary rate remains to be seen as no critical phenotypic changes were observed in our animal model experiments using viruses isolated from white-tailed deer. Still, SARS-CoV-2 viruses have transmitted in white-tailed deer populations for a relatively short duration, and the risk of future changes may have serious consequences for humans and livestock.
- 16 February 2023
- Published by Springer Nature in Research Square
Open AccessAccelerated evolution of SARS-CoV-2 in free-ranging white-tailed deer
While SARS-CoV-2 has sporadically infected a wide range of animal species worldwide1, the virus has been repeatedly and frequently detected in white-tailed deer in North America2–7. The zoonotic origins of this pandemic virus highlight the need to fill the vast gaps in our knowledge of SARS-CoV-2 ecology and evolution in non-human hosts. Here, we detected SARS-CoV-2 was introduced from humans into white-tailed deer more than 30 times in Ohio, USA during November 2021-March 2022. Subsequently, deer-to-deer transmission persisted for 2-8 months, which disseminated across hundreds of kilometers. We discovered that alpha and delta variants evolved in white-tailed deer at three-times the rate observed in humans. Newly developed Bayesian phylogenetic methods quantified how SARS-CoV-2 evolution is not only faster in white-tailed deer but driven by different mutational biases and selection pressures. White-tailed deer are not just short-term recipients of human viral diversity but serve as reservoirs for alpha and other variants to evolve in new directions after going extinct in humans. The long-term effect of this accelerated evolutionary rate remains to be seen as no critical phenotypic changes were observed in our animal model experiments using viruses isolated from white-tailed deer. Still, SARS-CoV-2 viruses have transmitted in white-tailed deer populations for a relatively short duration, and the risk of future changes may have serious consequences for humans and livestock.
- Open Access
- 6 January 2023
- Published by Springer Nature in Research Square
Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology
Influenza viruses remain a leading cause of global respiratory illness in humans. The suboptimal effectiveness of seasonal influenza vaccination underscores the need for a more comprehensive understanding of immune mediators of protection, especially in populations with diverse baseline immune profiles and exposure histories. While anti-influenza antibody titers are typically used to define correlates of protection, mounting evidence suggests a substantive role for innate and cellular immunity in determining tolerance and resistance during influenza virus infection. However, distinct cell subsets that correlate with protection against symptomatic influenza remain to be identified in humans. Here, we measured baseline cellular and serologic profiles in peripheral blood from 206 vaccinated or unvaccinated adult subjects enrolled in the 2018 SHIVERS-II cohort to determine how baseline variations in the cellular and humoral immune compartments contribute independently or synergistically to the risk of developing symptomatic influenza infection. Protection from symptomatic influenza correlated with increased individual frequencies of diverse and polyfunctional CD4 and CD8 T cells, cells associated with engagement of humoral responses including cTfh and mDCs, Th17 cells, and innate effector CD16-expressing cytotoxic and cytokine-producing NK cells. In contrast, increased susceptibility was predominantly attributed to nonspecific inflammatory populations including γδ T cells and activated CD16neg NK cells, as well as TNFα+ single-producing CD8 T cells. A trained random forest model categorizing symptomatic influenza cases identified that cellular covariates substantially improved model accuracy up to 86% over demographic and serologic factors alone (61%). A corresponding variable importance analysis showed cellular populations comprise 28 of the top 30 covariates (from 48 total), with the single most important factor being ICOS+ cTfh cells. Lastly, using a multivariate logistic regression model considering participant demographics, anti-influenza antibody titers, vaccination status, and cell population covariates, we quantified how these factors contribute to risk of symptomatic influenza infection. Protection was associated with a combination of lymphocyte populations including naïve, CD107a+, and Th17 CD4 T cells, and serologic factors including antibodies targeting neuraminidase. Increased risk of symptomatic influenza (95% subtype A) was associated with elevated anti-hemagglutinin antibodies against influenza B (Yamagata), along with γδ T cells and TNFα+ CD8 T cell single-cytokine producers. Together, these results demonstrate that the composition of pre-infection peripheral cell profiles is a stronger predictor of symptomatic influenza susceptibility than vaccination, demographics, or serology.
- 6 January 2023
- Published by Springer Nature in Research Square
Open AccessBaseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology
Influenza viruses remain a leading cause of global respiratory illness in humans. The suboptimal effectiveness of seasonal influenza vaccination underscores the need for a more comprehensive understanding of immune mediators of protection, especially in populations with diverse baseline immune profiles and exposure histories. While anti-influenza antibody titers are typically used to define correlates of protection, mounting evidence suggests a substantive role for innate and cellular immunity in determining tolerance and resistance during influenza virus infection. However, distinct cell subsets that correlate with protection against symptomatic influenza remain to be identified in humans. Here, we measured baseline cellular and serologic profiles in peripheral blood from 206 vaccinated or unvaccinated adult subjects enrolled in the 2018 SHIVERS-II cohort to determine how baseline variations in the cellular and humoral immune compartments contribute independently or synergistically to the risk of developing symptomatic influenza infection. Protection from symptomatic influenza correlated with increased individual frequencies of diverse and polyfunctional CD4 and CD8 T cells, cells associated with engagement of humoral responses including cTfh and mDCs, Th17 cells, and innate effector CD16-expressing cytotoxic and cytokine-producing NK cells. In contrast, increased susceptibility was predominantly attributed to nonspecific inflammatory populations including γδ T cells and activated CD16neg NK cells, as well as TNFα+ single-producing CD8 T cells. A trained random forest model categorizing symptomatic influenza cases identified that cellular covariates substantially improved model accuracy up to 86% over demographic and serologic factors alone (61%). A corresponding variable importance analysis showed cellular populations comprise 28 of the top 30 covariates (from 48 total), with the single most important factor being ICOS+ cTfh cells. Lastly, using a multivariate logistic regression model considering participant demographics, anti-influenza antibody titers, vaccination status, and cell population covariates, we quantified how these factors contribute to risk of symptomatic influenza infection. Protection was associated with a combination of lymphocyte populations including naïve, CD107a+, and Th17 CD4 T cells, and serologic factors including antibodies targeting neuraminidase. Increased risk of symptomatic influenza (95% subtype A) was associated with elevated anti-hemagglutinin antibodies against influenza B (Yamagata), along with γδ T cells and TNFα+ CD8 T cell single-cytokine producers. Together, these results demonstrate that the composition of pre-infection peripheral cell profiles is a stronger predictor of symptomatic influenza susceptibility than vaccination, demographics, or serology.
- Open Access
- 14 November 2022
- Published by Springer Nature in Research Square
Rapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America
Highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b underwent an explosive geographic expansion in 2021, with the viruses being detected in wild birds and domestic poultry across Asia, Europe, and Africa. In 2022, viruses of this clade were detected in North America, signifying further intercontinental spread. Here, we show that the western movement of clade 2.3.4.4b was quickly followed by reassortment with local circulating viruses, resulting in the acquisition of novel polymerase gene cassettes. These reassortant A(H5N1) viruses are genotypically and phenotypically diverse, with many causing severe disease with dramatic neurologic involvement, in mammals. The proclivity of the current A(H5N1) 2.3.4.4b virus lineage to reassort and target the central nervous system warrants concerted planning to combat the spread and evolution of the virus within the continent and to mitigate the impact of a potential influenza pandemic that could originate from similar A(H5N1) reassortants.
- 14 November 2022
- Published by Springer Nature in Research Square
Open AccessRapid evolution of A(H5N1) influenza viruses after intercontinental spread to North America
Highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b underwent an explosive geographic expansion in 2021, with the viruses being detected in wild birds and domestic poultry across Asia, Europe, and Africa. In 2022, viruses of this clade were detected in North America, signifying further intercontinental spread. Here, we show that the western movement of clade 2.3.4.4b was quickly followed by reassortment with local circulating viruses, resulting in the acquisition of novel polymerase gene cassettes. These reassortant A(H5N1) viruses are genotypically and phenotypically diverse, with many causing severe disease with dramatic neurologic involvement, in mammals. The proclivity of the current A(H5N1) 2.3.4.4b virus lineage to reassort and target the central nervous system warrants concerted planning to combat the spread and evolution of the virus within the continent and to mitigate the impact of a potential influenza pandemic that could originate from similar A(H5N1) reassortants.
- Top Cited PapersOpen Access
- 26 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (74) , eabo6294
ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), continues to cause substantial morbidity and mortality in the ongoing global pandemic. Understanding the fundamental mechanisms that govern innate immune and inflammatory responses during SARS-CoV-2 infection is critical for developing effective therapeutic strategies. Whereas interferon (IFN)–based therapies are generally expected to be beneficial during viral infection, clinical trials in COVID-19 have shown limited efficacy and potential detrimental effects of IFN treatment during SARS-CoV-2 infection. However, the underlying mechanisms responsible for this failure remain unknown. In this study, we found that IFN induced Z-DNA-binding protein 1 (ZBP1)–mediated inflammatory cell death, PANoptosis, in human and murine macrophages and in the lungs of mice infected with β-coronaviruses, including SARS-CoV-2 and mouse hepatitis virus (MHV). In patients with COVID-19, expression of the innate immune sensorZBP1was increased in immune cells from those who succumbed to the disease compared with those who recovered, further suggesting a link between ZBP1 and pathology. In mice, IFN-β treatment after β-coronavirus infection increased lethality, and genetic deletion ofZbp1or its Zα domain suppressed cell death and protected the mice from IFN-mediated lethality during β-coronavirus infection. Overall, our results identify that ZBP1 induced during coronavirus infection limits the efficacy of IFN therapy by driving inflammatory cell death and lethality. Therefore, inhibiting ZBP1 activity may improve the efficacy of IFN therapy, paving the way for the development of new and critically needed therapeutics for COVID-19 as well as other infections and inflammatory conditions where IFN-mediated cell death and pathology occur.
- 26 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (74) , eabo6294
Top Cited PapersOpen AccessZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), continues to cause substantial morbidity and mortality in the ongoing global pandemic. Understanding the fundamental mechanisms that govern innate immune and inflammatory responses during SARS-CoV-2 infection is critical for developing effective therapeutic strategies. Whereas interferon (IFN)–based therapies are generally expected to be beneficial during viral infection, clinical trials in COVID-19 have shown limited efficacy and potential detrimental effects of IFN treatment during SARS-CoV-2 infection. However, the underlying mechanisms responsible for this failure remain unknown. In this study, we found that IFN induced Z-DNA-binding protein 1 (ZBP1)–mediated inflammatory cell death, PANoptosis, in human and murine macrophages and in the lungs of mice infected with β-coronaviruses, including SARS-CoV-2 and mouse hepatitis virus (MHV). In patients with COVID-19, expression of the innate immune sensorZBP1was increased in immune cells from those who succumbed to the disease compared with those who recovered, further suggesting a link between ZBP1 and pathology. In mice, IFN-β treatment after β-coronavirus infection increased lethality, and genetic deletion ofZbp1or its Zα domain suppressed cell death and protected the mice from IFN-mediated lethality during β-coronavirus infection. Overall, our results identify that ZBP1 induced during coronavirus infection limits the efficacy of IFN therapy by driving inflammatory cell death and lethality. Therefore, inhibiting ZBP1 activity may improve the efficacy of IFN therapy, paving the way for the development of new and critically needed therapeutics for COVID-19 as well as other infections and inflammatory conditions where IFN-mediated cell death and pathology occur.
- Top Cited Papers
- 31 March 2022
- Published by Springer Nature in Nature
- Vol. 605 (7911) , 640-652
Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.
- 31 March 2022
- Published by Springer Nature in Nature
- Vol. 605 (7911) , 640-652
Top Cited PapersDefining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.
- Open Access
- 21 January 2022
- Published by SAGE Publications in Applied Biosafety
- Vol. 27 (2) , 58-63
It's the Wrong Virus: Rapid Adaptation of Operations Inside a Highly Pathogenic Avian Influenza Select Agent Laboratory in Response to the 2019 SARS-CoV-2 Pandemic
Background: The Animal Biosafety Level 3 Enhanced (ABSL-3+) laboratory at St. Jude Children's Research Hospital has a long history of influenza pandemic preparedness. The emergence of SARS-CoV-2 and subsequent expansion into a pandemic has put new and unanticipated demands on laboratory operations since April 2020. Administrative changes, investigative methods requiring increased demand for inactivation and validation of sample removal, and the adoption of a new animal model into the space required all arms of our Biorisk Management System (BMS) to respond with speed and innovation. Results: In this report, we describe the outcomes of three major operational changes that were implemented to adapt the ABSL-3+ select agent space into a multipathogen laboratory. First were administrative controls that were revised and developed with new Institutional Biosafety Committee protocols, laboratory space segregation, training of staff, and occupational health changes for potential exposure to SARS-CoV-2 inside the laboratory. Second were extensive inactivation and validation experiments performed for both highly pathogenic avian influenza and SARS-CoV-2 to meet the demands for sample removal to a lower biosafety level. Third was the establishment of a new caging system to house Syrian Golden hamsters for SARS-CoV-2 risk assessment modeling. Summary: The demands placed on biocontainment laboratories for response to SARS-CoV-2 has highlighted the importance of a robust BMS. In a relatively short time, the ABSL-3+ was able to adapt from a single select agent space to a multipathogen laboratory and expand our pandemic response capacity.
- 21 January 2022
- Published by SAGE Publications in Applied Biosafety
- Vol. 27 (2) , 58-63
Open AccessIt's the Wrong Virus: Rapid Adaptation of Operations Inside a Highly Pathogenic Avian Influenza Select Agent Laboratory in Response to the 2019 SARS-CoV-2 Pandemic
Background: The Animal Biosafety Level 3 Enhanced (ABSL-3+) laboratory at St. Jude Children's Research Hospital has a long history of influenza pandemic preparedness. The emergence of SARS-CoV-2 and subsequent expansion into a pandemic has put new and unanticipated demands on laboratory operations since April 2020. Administrative changes, investigative methods requiring increased demand for inactivation and validation of sample removal, and the adoption of a new animal model into the space required all arms of our Biorisk Management System (BMS) to respond with speed and innovation. Results: In this report, we describe the outcomes of three major operational changes that were implemented to adapt the ABSL-3+ select agent space into a multipathogen laboratory. First were administrative controls that were revised and developed with new Institutional Biosafety Committee protocols, laboratory space segregation, training of staff, and occupational health changes for potential exposure to SARS-CoV-2 inside the laboratory. Second were extensive inactivation and validation experiments performed for both highly pathogenic avian influenza and SARS-CoV-2 to meet the demands for sample removal to a lower biosafety level. Third was the establishment of a new caging system to house Syrian Golden hamsters for SARS-CoV-2 risk assessment modeling. Summary: The demands placed on biocontainment laboratories for response to SARS-CoV-2 has highlighted the importance of a robust BMS. In a relatively short time, the ABSL-3+ was able to adapt from a single select agent space to a multipathogen laboratory and expand our pandemic response capacity.